Hepatitis B News and Research

Latest Hepatitis B News and Research

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

New study to evaluate human immune system's response to influenza

The key to lasting protection against influenza may be in your bones. The cells that naturally protect you against illness originate and live in your bone marrow - and that is one spot where scientists will be looking to understand the human immune system's response to influenza in a groundbreaking new study led by the Human Vaccines Project.

1 Nov 2018

Study offers hope of early detection, treatment of liver cancer

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure -- but now a study offers hope of early detection, and targets for new treatments.

31 Oct 2018

Research reveals high stability of hepatitis B viruses

At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

30 Oct 2018

LKSOM and Hunter jointly receive $13.5 million grant from National Cancer Institute

The Lewis Katz School of Medicine at Temple University and Hunter College of the City University of New York have jointly received a five-year, $13.5 million grant from the National Cancer Institute.

30 Oct 2018

Researchers identify new potential target to inhibit progression of liver disease

Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease.

26 Oct 2018

Researchers find improvement in liver transplant survival rate among older recipients

An increasing number of older adults are diagnosed with end-stage liver disease. End-stage liver disease is a life-threatening condition in which the liver stops working normally.

23 Oct 2018

Map of human liver cells reveals molecular make-up of individual cells

A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular level which can have a profound impact on their behaviour in tissue, tumours and disease.

From 10x Genomics, Inc. 23 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

UT Southwestern biochemist Dr. Zhijian "James" Chen today was named winner of the prestigious 2019 Breakthrough Prize in Life Sciences for his discovery of the cGAS enzyme that launches the body's immune defense against infections and cancers.

19 Oct 2018

One-time universal screening recommended to tackle increase in hepatitis C

Physicians are encountering a growing number of younger patients who are testing positive for hepatitis C virus fueled largely by the opioid crisis impacting communities around the country.

17 Oct 2018

Antimicrobial signaling molecule has lower activity against hepatitis C virus in most humans

An antimicrobial signaling molecule called IFNλ4 has lower activity against the hepatitis C virus in the vast majority of humans compared with chimpanzees and African hunter-gatherer Pygmies, according to a study published October 11 in the open-access journal PLOS Pathogens by John McLauchlan’s research team at the MRC-University of Glasgow Centre for Virus Research in the UK, and colleagues.

12 Oct 2018

Researchers develop new techniques for faster detection of Lyme disease bacteria

Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

11 Oct 2018

Tobacco control must be highest priority in national cancer control plan, says report

The highest priority in a national cancer control plan must be expansion of tobacco control--the intervention with the largest potential health benefits--according to a new American Cancer Society report, the second in a series of articles that together inform priorities for a comprehensive cancer control plan.

11 Oct 2018

Research reveals new details of HIV life cycle

Research by a multi-institutional team, including two members from the University of Delaware, has revealed new details about the HIV virus capsid structure and how it develops.

5 Oct 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

New book provides evidence that new drugs, medical technologies are safe and effective

Does a new medicine or diagnostic test work? Is it safe? Should the government approve it and insurers pay for it? The answers are not as straightforward as they may seem - and the reasons are the subject of a new book by Karen J. Maschke, a research scholar at The Hastings Center, and Michael K. Gusmano, a Hastings Center research scholar and an associate professor of health policy at Rutgers University School of Public Health.

27 Sep 2018

Human-oriented perspective needed to better understand Parkinson's disease

Analysis published in Drug Discovery Today reveals the gap between animal models of Parkinson's disease and our understanding of the neurodegenerative processes underlying the disease, and calls for the implementation of modern, human biology-based technologies to better understand pathological processes and improve treatment outcome.

25 Sep 2018

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

Hepatitis B News and Research

Latest Hepatitis B News and Research

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

New study to evaluate human immune system's response to influenza

Study offers hope of early detection, treatment of liver cancer

Research reveals high stability of hepatitis B viruses

LKSOM and Hunter jointly receive $13.5 million grant from National Cancer Institute

Researchers identify new potential target to inhibit progression of liver disease

Researchers find improvement in liver transplant survival rate among older recipients

Map of human liver cells reveals molecular make-up of individual cells

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

One-time universal screening recommended to tackle increase in hepatitis C

Antimicrobial signaling molecule has lower activity against hepatitis C virus in most humans

Researchers develop new techniques for faster detection of Lyme disease bacteria

Tobacco control must be highest priority in national cancer control plan, says report

Research reveals new details of HIV life cycle

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

New book provides evidence that new drugs, medical technologies are safe and effective

Human-oriented perspective needed to better understand Parkinson's disease

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Hepatitis B News and Research

Latest Hepatitis B News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in